AdvisorShares Psychedelics ETF

Bright Minds Biosciences released FY2026 Q2 earnings on May 19, 2026 (EST), with actual revenue of USD 0 (forecast USD 0) and actual EPS of USD -0.7829 (forecast USD -0.9535)

Neurocrine Biosciences advances Phase II clinical trial for NBI-1065890

The Hill and Definium Therapeutics Host Forum on Psychedelic Therapy Prospects

AtaiBeckley Reports Q1 Net Loss of $29.78M, Stock Rises Amid Valuation Debate

Neurocrine Biosciences Director Richard F. Pops Sells 15,000 Shares for $2.36 Million

Neurocrine Biosciences Releases Real-World Data Confirming INGREZZA's Improvement in Tardive Dyskinesia

H.C. Wainwright Analyst Trucchio Maintains Buy Rating on COMPASS Pathways, Sets Target Price at $70

NRX Therapeutics released FY2026 Q1 earnings on May 15 Pre-Market (EST), actual revenue USD 1.068 M (forecast USD 19.43 M), actual EPS USD -0.0442 (forecast USD 0.208)

GH Research released FY2026 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.3057 (forecast USD -0.2633)

Alto Neuroscience released FY2026 Q1 earnings on May 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8 (forecast USD -0.5363)

Compass Pathways Submits Psilocybin Drug COMP360 for New Drug Application

Compass Pathways released FY2026 Q1 earnings on May 13 Pre-Market (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD 0.7001 (forecast USD -0.4472)

COMPASS Pathways plc Reports Q1 2026 Financials

AtaiBeckley released FY2026 Q1 earnings on May 12 (EST), actual revenue USD 954 K (forecast USD 90.91 K), actual EPS USD -0.0833 (forecast USD -0.1087)

Relmada Therapeutics released FY2026 Q1 earnings on May 12 During-Market EST, actual revenue USD 0 (forecast USD 0), actual EPS USD -0.22 (forecast USD -0.195)

Alkermes Announces Positive Top-Line Results for Lumryz® in Adult Idiopathic Hypersomnia Phase III Study

Definium Therapeutics Completes First Patient Dosing in DT120 ODT for Major Depressive Disorder Phase 3 Clinical Trial

NRX Therapeutics to Release FY2026 Q1 Earnings on May 18 Pre-Market EST, Forecast Revenue USD 19.43 M, EPS USD 0.208

Definium Therapeutics plans five Phase III studies for DT120 ODT targeting GAD and MDD

Definium Therapeutics Inc Reports Q1 EPS of $(0.71)

Optimi Health

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

PSIL

The article discusses the current state of cannabis investments and suggests considering psychedelics stocks instead. Cannabis stocks have faced challenges due to oversupply and regulatory uncertainties, leading to cautious sentiments among investors. Doug Kass, a trader, has exited most cannabis holdings, citing long-term risks. Meanwhile, psychedelics stocks are gaining attention following an executive order to accelerate research on substances like psilocybin. However, these stocks are also risky, often being small caps with low trading volumes. Investors are advised to approach with caution and consider ETFs like AdvisorShares Psychedelics ETF (PSIL).

Tip Ranks

AdvisorShares Pure US Cannabis ETF

Beyond Cannabis: 3 Stock Picks Tied to the Psychedelics Trade

CMPS

ATAI

CYBN

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

Barchart Option

Compass Pathways

AtaiBeckley

Cybin

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

The FDA has granted Compass Pathways a rolling review for its New Drug Application (NDA) for COMP360, a psychedelic therapy for treatment-resistant depression (TRD). This designation could expedite the review process to one to two months post-filing. Compass has reported positive results from two Phase 3 trials involving over 1,000 participants, indicating significant effects and manageable safety profiles. The decision reflects a growing regulatory interest in innovative treatments for mental health disorders, particularly for patients with limited options. The next step involves completing the NDA under the rolling review framework, with approval contingent on clinical evidence and product quality.

Pharmexec

<![CDATA[FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression]]>

The recent surge in interest in psychedelic stocks is linked to President Trump's executive order aimed at enhancing research and access to drugs like psilocybin and MDMA for treating mental illnesses. However, investing in these stocks carries risks due to their small market caps and low trading volumes, which can lead to wider spreads and potential profitability issues. The popularity of these stocks may also be fleeting, reminiscent of the decline seen in marijuana stocks, as exemplified by Tilray Brands' significant loss in value over the past five years.

Tilray Brands

3 Different Ways to Play the Rally in Psychedelic Stocks

Trump's recent executive order aims to expedite the review of psychedelic therapies, potentially attracting institutional investment. Compass Pathways, currently in phase 3 testing with promising data, stands out in the psychedelics sector. With $150 million in cash, the company is well-positioned to reach a regulatory decision without immediate dilution. Its lead asset, COMP360, shows significant efficacy for treatment-resistant depression. Compass has demonstrated strong institutional backing, owning 46% of its shares, and is funded to advance its late-stage development, although risks remain tied to regulatory approval and commercialization.

nasdaq

NVIDIA

Intel

Definium Therapeutics

Toronto Dominion Bank

UBS Group AG

NVIDIA Corporation

Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About

SEEL

SEELQ

HELP

SBIO

President Trump has signed an executive order to ease research restrictions on psychedelic medicine, inspired by a text from podcaster Joe Rogan. This move aims to legitimize an industry hindered by federal regulations since the 1970s. The order directs federal agencies to facilitate access to experimental treatments for terminally ill patients and allocates $50 million for state-level research into ibogaine. Advocates express cautious optimism about potential mental health benefits, although widespread access remains uncertain without further action. The FDA will also expedite approval processes for promising psychedelic therapies.

Thehill

Seelos Therapeutics

SEELOS THERAPEUTICS INC

iBio

Impact BioMedical

ALPS Medical Breakthrough

Ark Genomic Revolution ETF

Invesco Nasdaq Biotechnology ETF

iShares Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

VanEck Biotech ETF

Trump’s Rogan-inspired psychedelics order stokes cautious optimism

ENVB

LABU

An executive order from President Trump has led to a surge in stocks of biotechnology companies focused on psychedelics, as it aims to expedite the development of these drugs for mental health. The order includes provisions for the FDA to issue national priority vouchers for breakthrough psychedelic medicines and to facilitate patient access under the Right to Try Act. Analysts view this as a significant boost for the psychedelics sector, with companies like Enveric Biosciences seeing stock increases of nearly 200%. Overall, the order is expected to accelerate FDA reviews and enhance revenue potential for these companies.

biopharmadive

Enveric Biosciences

Direxion S&P Biotech Bull 3X

Jefferies Financial

GH Research

ROYAL BANK OF CANADA

Stifel Financial

Mind Medicine MindMed

Otsuka Holdings Co., Ltd.

Abbvie

Johnson & Johnson

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

Trump executive order lifts psychedelics biotechs

GHRS

DRUG

Donald Trump signed an executive order to accelerate research and access to psychedelic therapies, backed by $50 million in federal funding. This move aims to address the mental health crisis, particularly among veterans, and signals a shift in regulatory attitudes towards psychedelics. Advocates like Robert F. Kennedy Jr. and Joe Rogan support this change, which could legitimize an industry previously sidelined. While risks remain, the allocation of federal resources and expedited review timelines indicate a significant shift in perception and potential for the psychedelic sector.

ZeroHedge

Bright Minds Biosciences

iShares Global Healthcare

Psychedelic Stocks Just Went Mainstream

IXHL

Incannex Healthcare Limited announced advancements in its psilocybin program for generalized anxiety disorder, aligning with a recent U.S. policy shift to accelerate treatments for mental illness. The company is progressing three key product candidates and highlighted positive Phase 2 trial data. Despite a neutral rating from analysts due to financial performance concerns, Incannex's strong cash position and regulatory developments may enhance access to its therapies. The company focuses on innovative treatments for chronic conditions, including sleep apnea and rheumatoid arthritis.

Incannex Healthcare

VG Health

iShares US Pharma

Incannex Highlights Psilocybin Anxiety Program Amid U.S. Policy Shift

Incannex Healthcare aligns its PSX-001 program with a White House Executive Order, highlighting strong Phase 2 data that shows a significant reduction in anxiety symptoms. The Phase 2 trial reported a 12.8-point reduction in HAM-A scores compared to 3.6 for placebo, with a 44% clinically meaningful response and 27% remission sustained for 11 weeks. The company has over $70 million in cash, no debt, and an active U.S. IND, positioning it well for advancement amid regulatory changes.

TradingView

Incannex Healthcare aligns PSX-001 program with White House order, cites strong Phase 2 data and $70M cash

AdvisorShares Psychedelics ETF(PSIL.US)

Beyond Cannabis: 3 Stock Picks Tied to the Psychedelics Trade

Trump Wants to Give Psychedelics Stocks a Boost. Can This Leading Company Deliver?

<![CDATA[FDA Awards Priority Voucher to Compass for Psychedelic Therapy in Treatment-Resistant Depression]]>

3 Different Ways to Play the Rally in Psychedelic Stocks

Trump Backs Psychedelics. Here's 1 Company Investors Need to Know About